tbuckley/cabot-search huggingface dataset:
AB0854 Dysfunctional pain component in ankylosing spondylitis patients
Authors: E. Filatova, S. Erdes
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> As a result of chronic inflammation, repetitive activation of primary afferent fibres changes the functional state and activity of Central nervous pathways. On this patients when describing their complaints use neuropathic pain descriptors include numbness, burning, tingling, increased pain response to a stimulus nabulivou etc. <h3>Objectives</h3> The study of chronic pain syndrome in patients with ankylosing spondylitis (AS) to identify dysfunctional component of pain (DCP). <h3>Methods</h3> Was studied 150 patients as 127 men and 23 women. The average age of 35, and 52±10,55, mean disease duration of 7.19±of 6.31. All the patients were performed clinical and rheumatological examination (indices BASDAI, BASFI), the assessment of pain intensity on visual analogue scale (VAS), to identify DCP were investigated neurological status with the use of questionnaires neuropathic pain DN4 and PainDETECT, and identifying the emotional-affective disorders (HADS questionnaire). <h3>Results</h3> 22 patients (14.7%) on the DN4 questionnaire revealed 4 or more points, but lesions of the somatosensory nervous system in these patients was not detected, hence 14,7% of patients were identified DCP. When comparing patients with the presence of TCS group I (22 people) and no DCP group II (128) it has been found that statistically significantly in patients in group I had higher pain intensity on VAS (6,09±185 vs 4,55±2,06, p=0.001, respectively); active disease BASDAI index (of 7.05±vs 1,58 4,87±2,16, p=0.001, respectively); the expression of functional impairment index BASFI (6,46±2,24 vs 4,05±2,81, p=0.001); the indicators of the questionnaire HADS in group I, consistent with the presence of clinically significant anxiety and lack of it in group II (10,09±2,86 vs 6,17±3,35, p=0.0001). However, duration of disease distinguish authentic in the groups was not (9,41±6,89 6,81 vs ±6,13 p=0,07). Correlation analysis revealed a significant relationship between DCP and the intensity of the pain in VAS back, as well as with the severity of anxiety, disease activity, functional disorders (p=0.05) <h3>Conclusions</h3> The study identified 22 patients, the presence of neuropathic pain descriptors in combination with anxiety disorders, resulting in the conclusion that, along with nociceptive component of pain in 14.7% of cases detected by the DCT. So the pain of some AS patients should be considered as a multicomponent syndrome, providing a comprehensive approach with the use of antidepressants (TCA and SSRI's). <h3>Disclosure of Interest</h3> None declared
Abstract 11498: Inhibition of Phosphodiesterase Type 3 Dilates the Rat Ductus Arteriosus Without Inducing Intimal Thickening and Respiratory Distress
Authors: Yasuhiro Ichikawa, Utako Yokoyama, Mari Iwamoto, Munetaka Masuda, Toshihide Asou, Yoshihiro Ishikawa
Journal: Circulation (2012)

Prostaglandin E1 (PGE1), via cAMP, dilates the ductus arteriosus (DA). For patients with DA-dependent congenital heart diseases, PGE1 is the sole DA dilator used until surgery. However, PGE1 has a ...
Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study
Authors: Daniel H. Ryan, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna Hogge, Scott R Solomon, Richard M. Stone, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Robert Ryan, Michael Chiarella, Arthur C. Louie, Jeffrey E. Lancet
Journal: Blood (2018)
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
Authors: Josef Coresh, Hiddo J L Heerspink, Yingying Sang, Kunihiro Matsushita, Johan Arnlov, Brad C Astor, Corri Black, Nigel J Brunskill, Juan-Jesus Carrero, Harold I Feldman, Caroline S Fox, Lesley A Inker, Areef Ishani, Sadayoshi Ito, Simerjot Jassal, Tsuneo Konta, Kevan Polkinghorne, Solfrid Romundstad, Marit D Solbu, Nikita Stempniewicz, Benedicte Stengel, Marcello Tonelli, Mitsumasa Umesawa, Sushrut S Waikar, Chi-Pang Wen, Jack F M Wetzels, Mark Woodward, Morgan E Grams, Csaba P Kovesdy, Andrew S Levey, Ron T Gansevoort, Lawrence J Appel, Tom Greene, Teresa K Chen, John Chalmers, Hisatomi Arima, Vlado Perkovic, Adeera Levin, Ognjenka Djurdjev, Mila Tang, Joseph Nally, Sankar D Navaneethan, Jesse D Schold, Misghina Weldegiorgis, William G Herrington, Margaret Smith, C Yenchih Hsu, Shih-Jen Hwang, Alex R Chang, H. Lester Kirchner, Jamie A Green, Kevin Ho, Angharad Marks, Gordon Prescott, Laura E Clark, Nick Fluck, Varda Shalev, Gabriel Chodick, Peter J Blankestijn, Arjan Van Zuilen, Jan A Van den Brand, Mark J Sarnak, Erwin Bottinger, Girish N Nadkarni, Stephen G Ellis, Rajiv Nadukuru, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann, Marc Froissart, Timothy Kenealy, Raina C Elley, John F Collins, Paul L Drury, John K Cuddeback, Elizabeth L Ciemins, Rich Stempniewicz, Robert G Nelson, William C Knowler, Stephen J Bakker, Rupert W Major, James F Medcalf, David Shepherd, Elizabeth Barrett-Connor, Jaclyn Bergstrom, Joachim H Ix, Miklos Z Molnar, Keiichi Sumida, Dick de Zeeuw, Barry Brenner, Abdul R Qureshi, Carl-Gustaf Elinder, Bjorn Runesson, Marie Evans, Marten Segelmark, Maria Stendahl, Staffan Schön, David M Naimark, Navdeep Tangri, Maneesh Sud, Atsushi Hirayama, Kazunobu Ichikawa, Henk JG Bilo, Gijs WD Landman, Kornelis JJ Van Hateren, Nanne Kleefstra, Stein I Hallan, Shoshana H Ballew, Jingsha Chen, Lucia Kwak, Aditya Surapaneni, Hans-Henrik Parving, Roger A. Rodby, Richard D Rohde, Julia B Lewis, Edmund Lewis, Ronald D Perrone, Kaleab Z Abebe, Fan F Hou, Di Xie, Lawrence G Hunsicker, Enyu Imai, Fumiaki Kobayashi, Hirofumi Makino, Sadayoshi Ito, Giuseppe Remuzzi, Piero Ruggenenti, Kai-Uwe Eckardt, Hrefna Gudmundsdottir, Romaldas Maciulaitis, Tom Manley, Kimberly Smith, Norman Stockbridge, Aliza Thompson, Thorsten Vetter, Kerry Willis, Luxia Zhang
Journal: The Lancet Diabetes & Endocrinology (2019)
Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy
Authors: Qiong Jia, Fang Yang, Wei Huang, Yao Zhang, Binghao Bao, Ke Li, Fuxiang Wei, Cunyu Zhang, Haibo Jia
Journal: Theranostics (2019)

Tumorigenic cells, when facing a hostile environment, may enter a dormant state, leading to long-term tumor survival, relapse, and metastasis.To date, the molecular mechanism of tumor cell dormancy remains poorly understood.Methods: A soft, 3-dimentional (3D) fibrin gel culture system was used to mechanically select and grow highly malignant and tumorigenic melanoma tumor-repopulating cells (TRCs).We cultured control melanoma TRCs, TRCs with Sox2 knockdown, TRCs with Sox2 knockout, and a 2D control for in vitro and in vivo experiments.Western blotting, immunofluorescence, and flow cytometry analysis were performed to examine TRC dormancy and exit from dormancy.Results: Under a low-expression condition, we show that Sox2, a stemness molecule participates in dormancy regulation of highly tumorigenic cells that can repopulate a tumor (TRCs).Intriguingly, complete depletion of Sox2 via knockout results in dormancy exit and growth resumption of melanoma TRCs in culture and elevation of melanoma TRC apoptosis.Mice that are injected subcutaneously with Sox2-depleted melanoma TRCs do not form tumors and survive much longer than those injected with melanoma TRCs.We found that complete depletion of Sox2 promotes nuclear translocation of phosphorylated STAT3, where it binds to the p53 gene promoter, thus activating the p53-caspase3 cascade.Conclusion: These findings provide a novel insight into the role of the Sox2 gene in tumor cell stemness, tumor dormancy, and apoptosis.
Telomere length and genetic variant associations with interstitial lung disease progression and survival
Authors: Chad A. Newton, Justin M. Oldham, Brett Ley, Vikram Anand, Ayodeji Adegunsoye, Gabrielle Liu, Kiran Batra, Jose Torrealba, Julia Kozlitina, Craig Glazer, Mary E. Strek, Paul J. Wolters, Imre Noth, Christine Kim Garcia
Journal: European Respiratory Journal (2019)

Leukocyte telomere length (LTL), MUC5B rs35705950 and TOLLIP rs5743890 have been associated with idiopathic pulmonary fibrosis (IPF). In this observational cohort study, we assessed the associations between these genomic markers and outcomes of survival and rate of disease progression in patients with interstitial pneumonia with autoimmune features (IPAF, n=250) and connective tissue disease-associated interstitial lung disease (CTD-ILD, n=248). IPF (n=499) was used as a comparator. The LTL of IPAF and CTD-ILD patients (mean age-adjusted log-transformed T/S of −0.05±0.29 and −0.04±0.25, respectively) is longer than that of IPF patients (−0.17±0.32). For IPAF patients, LTL &lt;10th percentile is associated with faster lung function decline compared to LTL ≥10th percentile (−6.43% per year versus −0.86% per year; p&lt;0.0001) and worse transplant-free survival (hazard ratio 2.97, 95% CI 1.70–5.20; p=0.00014). The MUC5B rs35705950 minor allele frequency (MAF) is greater for IPAF patients (23.2, 95% CI 18.8–28.2; p&lt;0.0001) than controls and is associated with worse transplant-free IPAF survival (hazard ratio 1.92, 95% CI 1.18–3.13; p=0.0091). Rheumatoid arthritis (RA)-associated ILD (RA-ILD) has a shorter LTL than non-RA CTD-ILD (−0.14±0.27 versus −0.01±0.23; p=0.00055) and higher MUC5B MAF (34.6, 95% CI 24.4–46.3 versus 14.1, 95% CI 9.8–20.0; p=0.00025). Neither LTL nor MUC5B are associated with transplant-free CTD-ILD survival. LTL and MUC5B MAF have different associations with lung function progression and survival for IPAF and CTD-ILD.
AB0852 Gender differences in axial and peripheral spondyloarthritis: results from the esperanza cohort
Authors: C. Urrego Laurín, V. Navarro-Compán, P. Zurita, T. Ruiz Jimeno, C. Campos fernandez, J. Mulero Mendoza, E. De Miguel Mendieta
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with spondyloarthritis (SpA), published data indicate different manifestations and outcomes between genders. Nevertheless, the evidence in patients with early and peripheral disease is lacking. <h3>Objectives</h3> To evaluate differences in the presentation of the disease between genders in patients with early axial and peripheral SpA (axSpA, pSpA). <h3>Methods</h3> This study was carried out within the framework of the ESPeranza program, which was a Spanish multicenter initiative aiming to facilitate early diagnosis and follow-up of patients with SpA between 2008–11. Out of 775 patients referred, 377 patients fulfilled the ASAS classification criteria for SpA:291(77%) axSpA and 86 (23%) pSpA. Demographic and disease characteristics were compared between genders using Chi-square (for categorical variables) and Student t (for continuous variables) tests. <h3>Results</h3> In total, 241 (64%) patients were males (191 axSpA and 50 pSpA). In the axSpA group, males had more frequently radiographic sacroiliac damage, elevated CRP, HLA-B27 positive and morning stiffness, while females had higher values of ESR and more frequency of peripheral arthritis (table 1). Within the pSpA group, male gender was significantly associated with higher diagnostic delay, psoriasis and elevated CRP while women had higher rates of functional limitation and ESR values. <h3>Conclusions</h3> In patients with SpA, different disease manifestations between genders are observed already from the first stages of the disease. In patients with axSpA, males have worst prognostic factors compared with females. However, in pSpA, females report poorer functionality despite being diagnosed earlier than male patients. This difference in phenotypes may be relevant when therapeutic decision-making. <h3>Acknowledgements</h3> Project ESPeranza was funded by Pfizer through the Spanish Foundation of Rheumatology (FER), is currently supported by a restricted grant from the of Instituto de Salud Carlos III (FIS PI13/02034) and Fondos FEDER. <h3>Disclosure of Interest</h3> None declared
AB0269 Ankle synovitis and treat-to-target strategy in clinically and serologically different forms of rheumatoid arthritis, a single-centre experience
Authors: M. Kedves, J. Gál, K. Törőcsik, D. Balaton, J. Csitos, N. Megyes, G. Nagy
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> DAS28 based treat-to-target (T2T) strategy<sup><b>1</b></sup> was shown to improve outcomes in patients with rheumatoid arthritis (RA). Although previous studies have shown that approximately 1/3 of RA patients have foot symptoms[,<sup><b>2</b></sup> ankle and foot joints are not included in DAS28. <h3>Objectives</h3> To study the prevalence of ankle synovitis in clinically and serologically different forms of RA, treated according to the updated T2T strategy. <h3>Methods</h3> 1109 patients, with RA, treated according to the T2T approach were included in this study. Concurrent tenderness and swelling of the ankle joint were considered as synovitis. Rheumatoid factor (RF) and anti-mutated citrullinated vimentin (anti-MCV) positive and negative patients with different disease activity were evaluated. <h3>Results</h3> 8.47% (94) patients had high (DAS28 &gt;5.1); 35.25% (391) moderate (DAS28 ≤5.1;&gt;3.2) and 18.66% (207) low (DAS28 ≤3.2;≥2.6) disease activity. 37,6% (417) of patients were in clinical remission (DAS28 &lt;2.6). 60.71%<sup>17</sup> of anti-MCV and RF positive and 44.8%<sup>13</sup> of anti-MCV and RF negative patients with high disease activity had ankle synovitis (table 1). Regarding patients in remission, 13.7%<sup>18</sup> of anti-MCV and RF positive and 15%<sup>18</sup> of anti-MCV and RF negative patients had ankle synovitis (table 2). Interestingly, ankle synovitis was considerably more common than knee synovitis in all patient groups. <h3>Conclusions</h3> Our present data show that ankle synovitis is rather common in patients with serologically and clinically different forms of RA and highlight the importance of careful medical examination, even in case of clinical remission. <h3>References</h3> [1] Smolen JS, et al. Ann Rheum Dis. 2016Jan;75(1):3–15. [2] Dixey J, et al. J Rheumatol2004;69:48–54. <h3>Disclosure of Interest</h3> None declared
AB0449 Sdai reduction at week 2 predict the sdai remission at week 24 when certolizumab pegol (CZP) was administered to patients with rheumatoid arthritis
Authors: K. Oryoji, S.-I. Mizuki
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Certolizumab pegol (CZP) is approved for treatment of rheumatoid arthritis. <h3>Objectives</h3> To explore the predictor of efficacy of certolizumab pegol (CZP) for MTX-IR patients with rheumatoid arthritis in our retrospective study. <h3>Methods</h3> 50 patients who received CZP for rheumatoid arthritis of MTX-IR after 2013 were examined by losistic regression analysis using Age, sex, duration of disease, HAQ, TJC, SJC, gVAS, eVAS, CRP, SDAI, DAS 28-CRP, previous use of biologics, prednisolone use, ACPA, RF, the reduction rate of SDAI at week 2 to assess the predicting factor for SDAI remission at week 24. <h3>Results</h3> As a factor capable of achieving SDAI remission at 24 weeks after CZP administration, SDAI reduction rate of 50% or more (n=28, p&lt;0.001), females (p=0.01), the number of swollen joints (p=0.02) were extracted as significant factors. The odds ratio at which SDAI remission can be obtained at 24 weeks point is 15.4 (95% CI: 3.1–109.6) when the SDAI reduction rate at 2 weeks after the start of administration is 50% or more. SDAI remission rate at week 24 were 67% in SDAI reduction ≥50% at week 2 group and 22% in another. The continuation rate at week 24 in SDAI reduction ≥50% at week 2 is 93%. <h3>Conclusions</h3> When SDAI decreased by 50% or more at 2 weeks after initiation of CZP administration SDAI remission was easy to obtain after 24 weeks, and continuation rate was also good. <h3>Disclosure of Interest</h3> None declared
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Authors: Tanaz Sharifnia, Mathias J. Wawer, Ting Chen, Qing-Yuan Huang, Barbara A. Weir, Ann Sizemore, Matthew A. Lawlor, Amy Goodale, Glenn S. Cowley, Francisca Vazquez, Christopher J. Ott, Joshua M. Francis, Slim Sassi, Patricia Cogswell, Hadley E. Sheppard, Tinghu Zhang, Nathanael S. Gray, Paul A. Clarke, Julian Blagg, Paul Workman, Josh Sommer, Francis Hornicek, David E. Root, William C. Hahn, James E. Bradner, Kwok K. Wong, Paul A. Clemons, Charles Y. Lin, Joanne D. Kotz, Stuart L. Schreiber
Journal: Nature Medicine (2019)
AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response
Authors: Fieke W Hoff, Peter P. Ruvolo, Yihua Qiu, Michael Andreeff, Eveline S. de Bont, Terzah M. Horton, Steven M. Kornblau
Journal: Blood (2018)
Abstract 17322: The Impact of Pharmacy Outreach on Atrial Fibrillation Detection, Knowledge, and Medication Adherence in Hong Kong Elderly
Authors: Billy Wong, Anna Cheng, Erica Yip, Alex Wong, Bethany Wong, Bryan Yan, Ben Freedman, Vivian Lee
Journal: Circulation (2016)

Objectives: To estimate the prevalence and knowledge of atrial fibrillation (AF) in Hong Kong elderly population, and evaluate the effects of a pharmacy outreach intervention on AF knowledge and th...
Fabrication of Red Blood Cell-Based Multimodal Theranostic Probes for Second Near-Infrared Window Fluorescence Imaging-Guided Tumor Surgery and Photodynamic Therapy
Authors: Peiyuan Wang, Xuandong Wang, Qiang Luo, Yang Li, Xiaoxiao Lin, Lingling Fan, Yun Zhang, Jingfeng Liu, Xiaolong Liu
Journal: Theranostics (2019)

The therapeutic efficacy of fluorescence image-guided tumor surgery and photodynamic therapy (PDT) is impaired by the penetration depth limitation, low signal-to-noise ratio of traditional first near-infrared window (NIR I) fluorescence and the hypoxic tumor microenvironment. Here, a "red blood cell-based multimodal probe" was proposed to achieve enhanced tumor targeting and retention of fluorescent probes after an intravenous injection, so that second near-infrared window (NIR II) fluorescence bioimaging-guided complete tumor resection and high-efficiency photodynamic therapy could then be realized. Methods: The hexanoic acid ester-modified rose bengal (RB-HA), RGD (Arginine-Glycine-Aspartic) peptide and avidin were covalently coupled onto amine-modified upconversion nanoparticles (UCNPs) via EDC/NHS reaction (UCNPs@RB@RGD@avidin). Afterwards, the complex of ICG with bovine serum albumin (BSA) was loaded into RBCs through hypotonic dialysis (RBC@ICG). Then, the membrane proteins of RBC@ICG were biotinylated by biotin-modified phospholipids (RBC@ICG@biotin). Finally, the RBCp (Red Blood Cell based probe) was obtained by crosslinking UCNPs@RB@RGD@avidin to RBC@ICG@biotin through the interaction of avidin and biotin. The obtained multimodal RBCp was extensively characterized, both in vitro and in vivo, including analysis of chemical, physical and fluorescent features, O2 delivery ability, tumor accumulation, NIR II fluorescence bioimaging ability, photodynamic therapeutic efficiency, and biosafety. Results: The RBCp experienced efficient tumor targeting and long tumor retention for almost 4 h after intravenous injection, and the superior signal-to-noise ratio at the optimal time window can be used for guiding precise tumor resection under an 808-nm laser irradiation to facilitate lymph popliteal metastasis surgical delineation. Meanwhile, the RBCp can provide laser-responsive O2 release to enhance the PDT efficiency of popliteal lymph node metastasis under NIR II fluorescence bioimaging guidance. These excellent performances obviously lead to remarkably enhanced synergistic therapeutic effects of tumor surgery and metastatic inhibition. Conclusion: The proposed strategy will develop a new platform to increase surgical resection completeness and improve PDT efficiency, resulting in the successful and complete inhibition of tumor and metastasis, which could offer a promising approach for the clinical translation of malignant tumor treatment.
Appropriate use of Mohs micrographic surgery in immunocompromised patients is high, and published indications for Mohs decrease inappropriate use
Authors: Thuzar M. Shin, Victoria O'Malley, Scott Tuttle, Nicole Howe, Jeremy R. Etzkorn, Joseph F. Sobanko, David J. Margolis, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2019)
AB1175 Development and preliminary validation of an omeract mri enthesitis scoring system for the ankle in spondyloarthritis
Authors: A.J. Mathew, S. Krabbe, F. Gandjbakhch, R.G. Lambert, K.-G. Hermann, I. Eshed, P. Bird, W.P. Maksymowych, J.-D. Laredo, S.J. Pedersen, M.S. Stoenoiu, D. Glinatsi, I. Haugen, V. Foltz, J. Jaremko, R.P. Poggenberg, P.G. Conaghan, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Enthesitis is regarded the primary lesion in spondyloarthritis (SpA) and MRI allows sensitive visualisation of entheseal inflammation/damage, but no validated, internationally accepted scoring system exists. <h3>Objectives</h3> To develop and perform preliminary validation of a novel OMERACT MRI scoring system for assessing ankle enthesitis in SpA patients, and to improve this through iterative multi-reader scoring exercises and calibration sessions. <h3>Methods</h3> A systematic literature review of MRI studies on enthesitis in SpA identified key inflammatory and structural pathologies. Definitions were agreed by consensus within the OMERACT MRI in arthritis working group. Then, in a first internet-based multireader exercise the Achilles tendon and plantar fascia entheses in 10 ankle MRIs (sagittal T1W, sagittal and Axial T2W fat suppressed) were scored by 15 readers (3 radiologists and 12 rheumatologists), with varying expertise in ankle MRI, for tendon/fascia thickness/signal change, tendon/peritendon signal alteration, retrocalcaneal bursitis, bone spur, erosion and bone marrow oedema, using semi-quantitative scores (0–3: no/mild/moderate/severe pathology). After a subsequent calibration session leading to minor modifications of assessed parameters, 16 ankle MRIs (specifications as above), were scored by 15 readers in exercise 2 with a modified score sheet. Rules were agreed for scoring pathologies. In both exercises, scores for each reader for individual variables were compared and discussed, and mean scores for each variable were determined using descriptive statistics, as were sum scores. Inter-reader agreement was calculated using two-way consistency single measures intra-class correlation coefficient (ICC 3,1) for inflammatory and structural lesions. <h3>Results</h3> Exercise 1: Mean pairwise inter-reader ICC for combined score of inflammatory and structural variables was 0.65 (range 0.10–0.94), with 75% of values being good/very good (≥0.50). Discussion of results led to minor modifications of parameters to be assessed. Exercise 2: Inter-reader agreement (ICC) for all inflammatory variables combined ranged from 0.26–0.93 among reader pairs (mean 0.64; median 0.66; IQR 0.46–0.79). For structural variables combined ICC ranged from 0.05–0.91 among reader pairs (mean 0.45; median 0.45; IQR 0.2–0.6). <h3>Conclusions</h3> Initial steps in developing an OMERACT MRI heel enthesitis scoring system have demonstrated overall moderate reliability of the proposed variables. Further modification, refinement, calibration and validation (ongoing) are needed before this system is ready for use in SpA clinical trials. <h3>Disclosure of Interest</h3> None declared